The injury problem the study targets
The clinical question is why the remnant liver can fail after a large resection even when regeneration is attempted. The authors separate two failure modes: insufficient regeneration, where hepatocytes cannot rebuild functional mass, and irreversible damage, where programmed cell death removes functional hepatocytes. Their work addresses the second, arguing that pro-regenerative strategies alone may not rescue a liver that is actively losing cells.
The evidence base combines retrospective clinical data with male mouse models. Records from 371 cases covered anatomical left hemihepatectomy (30–40% resection, n = 174), right hemihepatectomy (50–60%, n = 145), and ALPPS (60–70%, n = 52). Alanine aminotransferase (ALT) peaked within 48–72 hours after surgery across these groups, defining an acute injury window in the first three days. In mice, 30%, 50%, and 70% PHx models showed injury scaling with resection size, with the 70% group worsening progressively over those three days.
Pyroptosis, not apoptosis, dominates the acute phase
Pyroptosis is a pro-inflammatory form of programmed cell death in which inflammasome signaling activates caspase-1, which cleaves gasdermin D; the GSDMD-N fragment then forms membrane pores and the cell releases IL-1β and IL-18. The paper distinguishes this from apoptosis because the two death modes imply different downstream consequences: pyroptosis recruits inflammation, while apoptosis is comparatively quiet.
Screening transcriptomic data across 21 cell death modes placed pyroptosis-related genes among the most strongly upregulated differentially expressed genes after 70% PHx. A GSVA pyroptosis score rose after 70% PHx and peaked at postoperative day 3 relative to controls and days 1–2. Western blots showed the corresponding proteins up, and ELISA confirmed IL-1β and IL-18 release. Single-cell RNA-seq scoring localized the pyroptosis signal to hepatocyte subpopulations across days 1–3, and multiplex immunofluorescence found GSDMD-N colocalizing strongly with the hepatocyte marker HNF4α but less with endothelial (CD31) or myeloid (CD11b) markers. Electron microscopy at day 3 showed membrane pore formation and swollen, ruptured mitochondria and endoplasmic reticulum.
The authors repeated the core validation in a 90% PHx model, where pyroptosis proteins again peaked at day 3 and cytokine release was progressive. That replication matters because it argues the mechanism is not specific to the 70% resection model, though both models remain mouse surgical settings.
A lipid burden precedes the membrane failure
Oil Red O staining confirmed intrahepatic lipid accumulation after PHx, following earlier signs of vacuolization on H&E and lipid droplets on electron microscopy. The upregulated pyroptosis-related genes were also enriched in lipid metabolism pathways, and the same pattern appeared in hepatocytes from 90% versus 70% PHx single-cell data.
The authors frame this as a transition from physiology to pathology. Transient regeneration-associated steatosis is normally an energy source for proliferation, but a sustained lipid influx that exceeds the liver's processing capacity can become a driver of injury. In their lipidomics, the burden persisted through the first three days after 70% PHx. They also tested the direction of the effect pharmacologically: reducing the lipid burden with WY-14643 mitigated remnant liver injury and improved survival in 90% PHx, while worsening it with ETO aggravated injury and survival. Those are the authors' experimental manipulations, not clinical interventions.
Phosphatidylcholine loss converts lipid load into ER stress
Phosphatidylcholine is a structural glycerophospholipid that helps set endoplasmic reticulum membrane properties. When its share falls, membrane fluidity changes and stress sensors such as PERK are engaged. The paper's causal chain runs from PC depletion to ER stress to pyroptosis, and the CHPT1 enzyme is the node that produces PC.
In an in vitro model combining hypoxia with palmitic acid, PC supplementation improved readouts of ER stress and cell viability, reduced lipid staining intensity, and lowered ER stress and pyroptosis proteins. In vivo, at day 3 after 70% PHx, PC supplementation lowered serum ALT, preserved organelle structure on electron microscopy, reduced damage area and lipid staining, and suppressed ER stress and pyroptosis markers. These experiments support PC as the lipid whose loss matters, but they are supplementation experiments in models, not evidence that raising PC rescues patients.
DR5 keeps FXR out of the nucleus
DR5 emerged from an intersection of RNA-seq differentially expressed genes, single-cell differentially expressed genes, WGCNA modules, and pyroptosis-related genes, followed by machine-learning ranking of key genes. The authors acknowledge that this ranking used 36 samples and 26 input genes, so they treat it as a screening aid rather than definitive evidence; the mechanistic claims rest on the separate multi-omics and experimental work.
Mechanistically, DR5 impedes FXR nuclear entry. FXR is a nuclear receptor that, when it reaches the nucleus, acts as a transcription factor. The paper reports co-immunoprecipitation and imaging consistent with DR5 restraining FXR in the cytosolic compartment, and FXR activation with GW4064 increased Chpt1 transcription in ChIP-qPCR assays, supporting direct positive regulation. Database analyses showed positive correlation between FXR (NR1H4) and CHPT1 expression in normal tissues.
Human ALPPS specimens provided the clinical correlate: patients with small-for-size syndrome had higher DR5 and reduced FXR/CHPT1 colocalization and expression than patients with smooth recovery. In 20 ALPPS patients, DR5 mRNA at stage 2 correlated with peak postoperative ALT, and the high-DR5 group had higher postoperative ALT than the low-DR5 group (10 patients each). These are associations in a small cohort, not proof that DR5 causes clinical failure.
Three interventions converge on one protective axis
The strongest test of the axis is whether independent entry points produce the same result. Hepatocyte-specific AAV-DR5 knockdown and the FXR agonist GW4064 both lowered ALT and AST and reduced liver injury in the 70% PHx model, while FXR inhibition with Z-GS worsened injury and abolished the protection from either treatment. Z-GS also lowered CHPT1 and raised pyroptosis markers, whereas knockdown or GW4064 raised CHPT1 and suppressed them.
The reverse experiment used AAV-DR5 overexpression. It markedly decreased mouse survival, raised ALT and AST, and enlarged the damage area; co-treatment with GW4064 mitigated the mortality trend and partially reversed the injury and the molecular signature, restoring CHPT1 while dampening NLRP3, GSDMD-N, cleaved caspase-1, and IL-1β. Because DR5 suppression, FXR activation, and PC supplementation all alleviate injury, the convergence supports the ordering DR5 → FXR → CHPT1 → PC → ER stress → pyroptosis.
Where the conclusion stops
The work is in male mice and human tissue samples, so sex-specific effects and causal direction in patients remain open. The authors note that small-for-size syndrome involves more complex portal hemodynamics and inter-individual metabolic variability, and that the clinical relevance of the DR5–FXR axis needs validation in larger cohorts. They also flag unresolved questions about whether glycerophospholipid regulation of pyroptosis is hepatocyte-specific, how it interacts with the hepatic immune microenvironment, and what the optimal therapeutic window would be.
The practical priority the paper establishes is a shift in target: from only promoting regeneration to reducing injury by protecting the glycerophospholipid pathway. Within the evidence, the most informative comparison is that DR5 overexpression worsened survival while restoring the downstream node with GW4064 partially reversed it, which places CHPT1 and PC downstream of DR5 as the more direct lever. Whether FXR activation or PC supplementation is the better candidate, and in which resection scenario, is not settled by these data.
Sources used in this answer
Multi-omics reveals the DR5-FXR-CHPT1 axis governs hepatocyte pyroptosis via glycerophospholipid remodeling after major partial hepatectomy in male mice
In male mouse PHx models and human ALPPS tissue, DR5 restrains FXR nuclear entry, lowering CHPT1 transcription and phosphatidylcholine production, which drives ER stress and hepatocyte pyroptosis; DR5 suppression, FXR activation, or PC supplementation alleviated post-surgical liver injury.